Anti-Rheumatic Rx
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 3 months ago
#EULAR2021 - Key points from Dr. Mease's oral abstract:
⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD
⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts
⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status
@Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 3 months ago
#EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow
Paul Studenic Stiddyo
4 years 3 months ago
#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow
Eric Dein ejdein1
4 years 3 months ago
OP0010 at #EULAR2021. FLORA trial: Fecal microbiota transplant as add-on Rx to MTX. Small trial showing time-to-event curves show inferiority to sham but good safety. Fascinating concept exploring gut-joint interaction. @RheumNow. https://t.co/BIOmA5z6vK
Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Poster Hall